Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
Authors:
- 15 April 2022
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 115 (5) , 611-615
Abstract
We evaluated anti-spike protein antibody (anti-S) production in 130 hematopoietic stem cell transplant (HSCT) recipients who received the coronavirus disease-2019 vaccine. Sixty-five received allo-HSCT and 65 received auto-HSCT. Disease-specific treatments were being administered to 43.1% of allo-HSCT and 69.2% of auto-HSCT patients. Seropositivity was observed in 87.7% of allo-HSCT and 89.2% in auto-HSCT patients. Anti-S antibody production was significantly impaired in auto-HSCT patients compared with controls (178U/mL [0.4–4990.0] vs. 669 U/mL [40.3–4377.0], p < 0.001), but not in allo-HSCT patients (900 U/mL [0.4–12,893.0] vs. 860 U/mL [40.3–8988.0], P = 0.659). Clinically relevant anti-S antibody levels (> 264 U/mL) were achieved in 59.2% of patients (76.9% in allo-HSCT and 41.5% in auto-HSCT). The main factors influencing the protective level of the antibody response were the CD19 + cell count and serum immunoglobulin G levels, and these were significant in both allo-HSCT and auto-HSCT patients. Other factors included time since HSCT, complete remission status, use of immunosuppressive drugs, and levels of lymphocyte subsets including CD4, CD8 and CD56 positive cells, but these were only significant in allo-HSCT patients. Allo-HSCT patients had a relatively favorable antibody response, while auto-HSCT patients had poorer results.Keywords
This publication has 13 references indexed in Scilit:
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsNew England Journal of Medicine, 2021
- Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipientsBlood, 2021
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational studyThe Lancet, 2021
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative AssaysMicrobiology Spectrum, 2021
- Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassayJournal of Virological Methods, 2021
- COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective surveyLeukemia, 2021
- Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2Nature Medicine, 2021
- Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort studyThe Lancet Haematology, 2021
- Adaptive immunity to SARS-CoV-2 and COVID-19Cell, 2021